Chemical subgroup
L01ED – Anaplastische Lymphomkinase (ALK)-Inhibitoren
12Decisions
20Patient groups
Added benefit by patient group
- Major1
- Considerable4
- Minor2
- Non-quantifiable1
- Not proven12
Decisions, newest first
- 2025-01-16AlecensaAlectinibMajor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-09-01LorviquaLorlatinibNot proven
- 2020-10-15AlunbrigBrigatinibConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2019-11-22LorviquaLorlatinibNot proven: 2 of 2 patient groups
- 2019-07-04AlunbrigBrigatinibNot proven
- 2018-06-21AlecensaAlectinibNon-quantifiable
- 2018-02-01ZykadiaCeritinibNot proven
- 2017-10-19AlecensaAlectinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-03-16XalkoriCrizotinibNot proven: 3 of 3 patient groups
- 2017-03-16ZykadiaCeritinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-12-15XalkoriCrizotinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-06-16XalkoriCrizotinibConsiderable
Data status: 2026-10-29